Pfizer must pay $142 million for the marketing and prescribing of epilepsy drug Neurontin for unapproved uses, a federal appeals court has ruled. The justices refused to overturn a jury's previous verdict. The jury determined Pfizer marketed Neurontin for bipolar disorder, migraines and neuropathic pain. The Food and Drug Administration had not approved the medicine for any of those uses.
EarlySense recently introduced a new patient monitoring system for providers. The EarlySense System monitors heart rate and respiration.
EarlySense Ltd. has received federal clearance for its EverOn Touch system. The product provides continuous resident monitoring. Online alerts let staff know when a resident has moved. This helps staff better identify low-movement residents. Such residents can be turned, which dramatically reduces their chances of developing pressure ulcers, the firm notes.